Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
299.78
+1.53 (0.51%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Penumbra Revenue
Penumbra had revenue of $324.14M in the quarter ending March 31, 2025, with 16.32% growth. This brings the company's revenue in the last twelve months to $1.24B, up 13.17% year-over-year. In the year 2024, Penumbra had annual revenue of $1.19B with 12.86% growth.
Revenue (ttm)
$1.24B
Revenue Growth
+13.17%
P/S Ratio
9.33
Revenue / Employee
$275,578
Employees
4,500
Market Cap
11.61B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.19B | 136.09M | 12.86% |
Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
PEN News
- 3 days ago - Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst - Benzinga
- 4 days ago - Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Penumbra, Inc. Reports First Quarter 2025 Financial Results - PRNewsWire
- 24 days ago - Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 - PRNewsWire
- 26 days ago - Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits - PRNewsWire
- 2 months ago - Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors - PRNewsWire
- 2 months ago - Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook - Benzinga
- 2 months ago - Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript - Seeking Alpha